AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients

AbbVie Inc ABBV announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). 

The results demonstrated a compelling overall response rate per independent central review (ICR) of 35% and 23% across c-Met High and c-Met Intermediate patients, respectively.

In addition, other endpoints demonstrated meaningful clinical outcomes, including a median duration of response per ICR of 9 months and 7.2 months and a median overall survival of 14.6 months and 14.2 months across c-Met High and c-Met Intermediate patients, respectively.

The safety profile of Teliso-V was consistent with previous findings, and no new safety concerns were identified. Adverse events with Teliso-V monotherapy were generally well managed and tolerated. 

Approximately 85% of lung cancers are classified as NSCLC. C-Met protein overexpression is found in approximately 25% of advanced EGFR wild-type NSCLC patients.

Teliso-V is being evaluated as a monotherapy in patients with previously treated c-Met overexpressing EGFR wild-type nonsquamous NSCLC in the randomized Phase 3 study TeliMET NSCLC-01, which is currently enrolling.

Price Action: ABBV shares are up 0.60% at $138.91 on the last check Wednesday.

Photo Via Company